\"

Day Two

8:30 AM - 8:50 AM Registration and Coffee

8:50 AM - 9:00 AM Chairman's Opening of Day Two

9:00 AM - 9:40 AM Generation of Precise Genome Edited Cell Lines for Drug Discovery: Opportunities, Challenges and Developments.

Speaker, Senior Research Scientist in Cellular Reagents and Assay Development in Discovery Sciences , AstraZeneca
  • How precise genome editing in cell line generation contributes to AstraZeneca’s drug discovery process.
  • Looking back: successes and challenges of cell line generation and what we have learnt.
  • Looking forward: what can we do to improve cell line generation to increase the success rate and make higher quality models faster.

img

Speaker

Senior Research Scientist in Cellular Reagents and Assay Development in Discovery Sciences
AstraZeneca

9:40 AM - 10:10 AM The CRISPR IP landscape: Understanding the Role of Patents in CRISPR

Catherine Coombes, Senior Patent Attorney, HGF Limited
  • Learn what the implications are for securing commercial protection with CRISPR
  • Understand the relevance of the new patents and what it means for development of the technique in your re
  • Hear what different applications mean in terms of the relevant intellectual property surrounding this down of gene editing in the different approaches to this technique

img

Catherine Coombes

Senior Patent Attorney
HGF Limited

11:25 AM - 11:55 AM Coffee Break

11:55 AM - NaN:NaN AM Assessing autophagy gene function using CRISPR genome editing and siRNA silencing

Speaker, Group Lead, MRC Laboratory for Molecular Biology and University College London
  • Understand the used of arrayed CRISPR libraries for high-throughput/high-content screening;
  • Compare CRISPR editing with siRNA silencing
  • Gain insight into the regulation of autophagy based on results obtained from using these technologies

img

Speaker

Group Lead
MRC Laboratory for Molecular Biology and University College London

12:35 PM - NaN:NaN AM Synthetic lethal interaction between the tumour suppressor STAG2 and its paralog STAG1

Speaker, Division of Cancer Studies, King's College London, The Francis Crick Institute
  • Hear how genome analysis identified mutation in all member of the cohesion complex and tumour suppressor cells, making them valuable candidates for development of targeted cancer therapy
  • Learn how different combinations of siRNAs and CRISPR knock out assays can be used to evaluate the synthetic lethal interaction between STAG1 and STAG2.
  • Explore how STAG1 may be an effective candidate for the development of targeted therapy for tumors harboring STAG2 loss of function mutations.

img

Speaker

Division of Cancer Studies
King's College London, The Francis Crick Institute

1:15 PM - 2:15 PM Networking Lunch

2:15 PM - 2:55 PM Utilizing The CRISPR/Cas9-Mediated Genome Editing To Model The Non-Coding Genetic Variants At Human Cancer Susceptibility Loci

- Utilize CRISPR/Cas9 knock-out and knock-in systems in human
Cancer cell lines to validate the cancer GWAS-associated genetic mutations.
- Utilize isogenic cell models and high-throughput drug screens to develop new drugs or new drug combinations for cancer chemotherapy.
- Apply the knowledge gained from the CRISPR/Cas9 applications to better understand the cancer risk, progression and evolution.

2:55 PM - NaN:NaN AM Discovery of Synthetic Lethal Interactions for Precision Oncology and Radiotherapy

- Understand how to develop novel organoid based models for translational cancer research and radiation oncology
- Apply high throughput clonal bar coding and longitudinal tracing of heterogeneous tumor cell populations for understanding the intratumoral response towards cancer and radiation therapy.
- Identify resistance mechanisms in radiotherapy using genome wide cancer entity specific tailored CRISPR/Cas9 libraries in vivo

3:35 PM - NaN:NaN AM Maintaining Control of the Repair Pathway When the Double Strand Break is Made

  • Learn how the right guide can help manipulate NHEJ post DSB
  • Uncover how NHEJ can be shifted through the right modifications of the knockout gene and with the use of smaller nucleotides
  • Hear what needs to be considered in order to improve the success rate of inserting the right DNA, RNA or Protein complex

4:15 PM - 4:30 PM Chairman's closing summary